Haisco Pharmaceutical Group Co., Ltd.

This phase 3 study tests whether an inhaled medication called HSK39004 can improve lung function in people with moderate to severe chronic obstructive pulmonary disease (COPD). Participants receive either the drug or a placebo twice daily for 24 weeks. The main goal is to measure…

This Phase 3 trial tests whether the drug HSK31679 can safely improve liver health in 400 adults with MASH, a serious fatty liver disease. Participants will take either the drug or a placebo daily for about a year. The main goals are to see if the drug can reverse liver inflammat…

This study tests the long-term safety and effectiveness of an experimental inhaler called HSK39004 in 300 adults aged 40 to 80 with moderate-to-severe COPD. Participants will use the inhaler twice daily for 52 weeks. The main goal is to monitor side effects and see how well the t…

This study tests a new tablet, HSK44459, for people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. About 420 adults aged 40 and older will receive either the drug or a placebo for 52 weeks. The main goal is to see if the drug he…

This Phase 3 trial tests whether HSK44459 tablets can slow the decline in lung function for adults with progressive pulmonary fibrosis, a condition where lung scarring worsens over time. About 378 participants will take the drug or a placebo twice daily for 52 weeks. The main goa…

This study looks at the long-term safety of an experimental inhaler called HSK39004 for people with moderate-to-severe chronic obstructive pulmonary disease (COPD). About 300 adults aged 40 to 80 will use the inhaler twice daily for 52 weeks. Researchers will monitor side effects…

This study tests a new drug called cofrogliptin against an older drug, acarbose, in 200 adults with type 2 diabetes who have never taken diabetes medication. The goal is to see which drug better lowers blood sugar levels and has fewer side effects. Participants will take one of t…

This phase 2 trial tests an oral tablet called HSK47388 in 220 adults with moderate-to-severe plaque psoriasis. Participants take the drug or a placebo once daily for 16 weeks. The main goal is to see if the drug can reduce psoriasis severity by at least 75% compared to placebo.

This phase 2 trial tests an oral drug called HSK44459 for adults with moderate to severe plaque psoriasis. About 150 participants will receive either the drug or a placebo for 16 weeks. The main goal is to see if the drug can reduce psoriasis skin symptoms by at least 75%.

This study tests a new drug called HSK55718 for pain after orthopedic surgery. About 200 adults will receive either the new drug, morphine, or a placebo. Researchers will measure how well it controls pain and how satisfied patients are. The goal is to find a safer or more effecti…

This study tests a new anesthesia drug called cipepofol in 400 children aged 3 to 17 who need surgery. The goal is to see if it works as well as the standard drug propofol for putting kids to sleep before surgery, and if it causes less pain at the injection site. The drug is give…